Navigation Links
Perrigo Expands Infant Formula Distribution in China With Founder Group

ALLEGAN, Mich., Oct. 19, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has entered into a supply agreement with Founder Pharma Co., Ltd., a wholly owned subsidiary of publicly listed Southwest Synthetic Pharmaceutical Corp., Ltd. (SZSE: 000788).  Perrigo will supply infant formula manufactured in its U.S. facilities, for sale and distribution by Founder Pharma in China.

Perrigo Chairman and CEO Joseph C. Papa stated, "Southwest Synthetic is an exciting partner given its strong reputation and healthcare focus. Perrigo's high quality products and Southwest Synthetic's strong brand, marketing, and distribution should be a winning combination in the world's most robust infant formula market."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (

Southwest Synthetic is located in Chongqing, China and is the largest manufacturing, R&D, and exporting enterprise of biological and chemical synthetic pharmaceutical products in southwest China. It is also a key enterprise in China's pharmaceutical industry and is one of China's pharmaceutical enterprises with the most international approvals. In the past 2 to 3 years, it has completed two consolidations and built an industry chain from biological and chemical pharmaceuticals to healthcare products distribution. Visit Southwest Synthetic on the Internet (

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 25, 2011, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company Will Release First Quarter Fiscal 2012 Results On October 27, 2011
2. Perrigo Company Confirms FDA Tentative Approval for Clobetasol Propionate Emulsion Foam
3. Perrigo to Host Analyst Day on October 5, 2011 at the TASE, Tel Aviv Stock Exchange in Tel Aviv, Israel
4. Perrigo to Host Analyst Day on September 27, 2011 at the NASDAQ MarketSite in Times Square
5. Perrigo Announces FDA Final Approval for Ketoconazole Foam, 2%
6. Perrigo Company Will Release Fourth Quarter Fiscal 2011 Results on August 16, 2011
7. Watson Enters into Agreement to Acquire Products Related to Perrigos Acquisition of Paddock Laboratories
8. Perrigo Closes Acquisition of Paddock Labs
9. Perrigo Receives FDA Approval to Market Coated Cinnamon Nicotine Gum
10. Perrigo Provides Update on Acquisition of Paddock Labs
11. Perrigo Announces Launch of the Generic Version of Nasacort® AQ
Post Your Comments:
(Date:11/24/2015)... , Nueva York , ... Biomedical Devices (ABD), fabricante del Avery Breathing Pacemaker ... Anders Jonzon , MD; Ph.D. como consultor clínico. ...   --> Foto - ... --> El doctor Jonzon es un fisiólogo ...
(Date:11/24/2015)... 24, 2015 --> ... Biologics Market by Product Type (Bone Graft, Bine Graft Substitute, ... Fusion, Posterior Lumbar Interbody Fusion), End User, and Geography - ... was valued at $1.90 Billion in 2014 and is expected ... 4.4% during the forecast period of 2015 to 2020. ...
(Date:11/24/2015)... FRAMINGHAM, Mass. , Nov. 24, 2015   ... leading innovator of less-invasive, miniaturized circulatory support technologies that ... announced that President and Chief Executive Officer Doug ... Jaffray 27 th Annual Healthcare Conference on December ... being held December 1-2 in New York ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... ... Dr. Todd S. Afferica, a noted general dentist in Norcross, GA ... Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many of his dental procedures. ... traditional cutting tools, such as the scalpel and high-speed drill, which can both cause ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Charitable giving ... charitable donations are made in the last five weeks of the year totalling over ... created in 2012 to connect the nation’s charities with those individuals who want to ...
(Date:11/24/2015)... (PRWEB) , ... November 25, 2015 , ... ... technologies and development solutions for drugs, biologics, consumer health and global clinical supply ... present at the upcoming Clinical Trial Supply East Asia Conference, to be held ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Preparing for ... p.m. – 3:00 p.m. EST, , FDA has long asserted that ... regulations apply to performing the tests and do not meet the device regulations. , ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... LENR HHT Bolier Reactor System. Brillouin is the developer of renewable energy technologies ... low energy nuclear reactions (“LENR”), announced today that its WET™ and HHT™ Boiler ...
Breaking Medicine News(10 mins):